Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The worldwide shortage of donor livers for organ and hepatocyte transplantation has prompted the search for alternative therapies for intractable liver diseases. Cell-based therapy is envisaged as a useful therapeutic option to recover and stabilize the lost metabolic function for acute liver failure, end-stage and congenital liver diseases, or for those patients who are not considered eligible for organ transplantation. In recent years, research to identify alternative and reliable cell sources for transplantation that can be derived by reproducible methods has been encouraged. Human pluripotent stem cells (PSCs), which comprise both embryonic and induced PSCs, may offer many advantages as an alternative to hepatocytes for liver cell therapy. Their capacity for expansion, hepatic differentiation and self-renewal make them a promising source of unlimited numbers of hepatocyte-like cells for treating and repairing damaged livers. Immunogenicity and tumorigenicity of human PSCs remain the bottleneck for successful clinical application. However, recent advances made to develop disease-corrected hepatocyte-like cells from patients' human-induced PSCs by gene editing have opened up many potential gateways for the autologous treatment of hereditary liver diseases, which may likely reduce the risk of rejection and the need for lifelong immunosuppression. Well-defined methods to reduce the expression of oncogenic genes in induced PSCs, including protocols for their complete and safe hepatic differentiation, should be established to minimize the tumorigenicity of transplanted cells. On top of this, such new strategies are currently being rigorously tested and validated in preclinical studies before they can be safely transferred to clinical practice with patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Balzan, S., Belghiti, J., Farges, O., Ogata, S., Sauvanet, A., Delefosse, D., & Durand, F. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000189131.90876.9e · Cited by 1,027
Laurent, L. C., Ulitsky, I., Slavin, I., Tran, H., Schork, A., Morey, R., Lynch, C., Harness, J. V., Lee, S., Barrero, M. J., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2010.12.003 · Cited by 890 · cited 1×
“Numerous deletions of tumorsuppressor genes in iPSCs have been found immediately after pluripotency induction, which were absent from the somatic cells of origin.(126) A recent analysis of the tumorigenic genes of several iPSCs lines has revealed 593 iPSC consensus genes, of which almost half were also expressed in hu…”
BackgroundThe tumorigenicity of human embryonic and induced pluripotent stem cells
Ben-David, U., & Benvenisty, N. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3034 · Cited by 889
Generation of Functional Human Hepatic Endoderm From Human Induced Pluripotent Stem Cells
Sullivan, G. J., Hay, D. C., Park, I.-H., Fletcher, J., Hannoun, Z., Payne, C. M., Dalgetty, D., Black, J. R., Ross, J. A., Samuel, K., et al. (2010) · Hepatology · doi:10.1002/hep.23335 · Cited by 445
Human hepatocyte transplantation: current experience and future challenges
Dhawan, A., Puppi, J., Hughes, R. D., & Mitry, R. R. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.44 · Cited by 362 · cited 10×
“Hepatocytes can be obtained from fetal livers, or fromunused neonatal or adult livers, for OLT.”
BackgroundResultInfluentialKhan, A. A., Shaik, M. V., Parveen, N., Rajendraprasad, A., Aleem, M. A., Aejaz, M., Srinivas, G., Avinash, T., Tiwari, S. K., Kumaresan, K., et al. (2010) · Cell Transplantation · doi:10.3727/096368910x498241 · Cited by 183
Cited by
Engineering Liver Microtissues for Disease Modeling and Regenerative Medicine
Huang, D. (., Gibeley, S. B., Xu, C., Xiao, Y., Celik, O., Ginsberg, H. N., & Leong, K. W. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909553 · Cited by 65
Stem cell therapy in Alzheimer’s disease: possible benefits and limiting drawbacks
Alipour, M., Nabavi, S. M., Arab, L., Vosough, M., Pakdaman, H., Ehsani, E., & Shahpasand, K. (2019) · Molecular Biology Reports · doi:10.1007/s11033-018-4499-7 · Cited by 63
Gao, X., Li, R., Cahan, P., Zhao, Y., Yourick, J. J., & Sprando, R. L. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01914-1 · Cited by 40
Clinical application of stem cell in patients with end-stage liver disease: progress and challenges
Tao, Y.-C., & Chen, E.-Q. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.153 · Cited by 15
Metadata
- Authors
- Tolosa, L., Pareja, E., & Gómez-Lechón, M. J.
- Venue
- Transplantation
- Published
- 2016-12
- Volume
- 100
- Issue
- 12
- Pages
- 2548-2557
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2508506114
- Cited by
- 40
- References
- 7
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases? https://app.cochat.ai/papers/10.1097/tp.0000000000001426
- The paper
- Tolosa, L., Pareja, E., & Gómez-Lechón, M. J. (2016). Clinical Application of Pluripotent Stem Cells: An Alternative Cell-Based Therapy for Treating Liver Diseases? Transplantation. https://doi.org/10.1097/tp.0000000000001426
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.